Maravai LifeSciences is planning an initial public offering (IPO) to raise up to $1.35 billion. The company is most well known for its mRNA and RNA products, which are used in vaccine development. Most notably, its CleanCap approach is being used in several vaccine trials for COVID-19, though it's too soon to tell if any of those particular vaccines will make it to market.
Here's what we know so far about the IPO, including how to buy in when the stock goes public.
The Finder Score crunches 147 key metrics we collected directly from 18+ brokers and assessed each provider’s performance based on nine different categories, weighing each metric based on the expertise and insights of Finder’s investment experts. We then scored and ranked each provider to determine the best brokerage accounts.
We update our best picks as products change, disappear or emerge in the market. We also regularly review and revise our selections to ensure our best provider lists reflect the most competitive available.
Paid non-client promotion. Finder does not invest money with providers on this page. If a brand is a referral partner, we're paid when you click or tap through to, open an account with or provide your contact information to the provider. Partnerships are not a recommendation for you to invest with any one company. Learn more about how we make money.
Finder is not an advisor or brokerage service. Information on this page is for educational purposes only and not a recommendation to invest with any one company, trade specific stocks or fund specific investments. All editorial opinions are our own.
| Latest market close | $2.07 |
|---|---|
| 52-week range | $1.67 - $11.56 |
| 50-day moving average | $2.38 |
| 200-day moving average | $5.81 |
| Wall St. target price | $5.10 |
| PE ratio | N/A |
| Dividend yield | N/A |
| Earnings per share (TTM) | $-1.05 |
The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.
This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.
Historical closes compared with the close of $2.07 from 2025-05-02
| 1 week (2025-04-29) | 2.07 |
|---|---|
| 1 month (2025-04-04) | 6.70% |
| 3 months (2025-02-06) | -58.18% |
| 6 months (2024-11-06) | -74.22% |
| 1 year (2024-05-06) | -77.03% |
|---|---|
| 2 years (2023-05-05) | -85.69% |
| 3 years (2022-05-05) | 28.55 |
| 5 years (2020-05-02) | N/A |
| Revenue TTM | $259.2 million |
|---|---|
| Gross profit TTM | $108.3 million |
| Return on assets TTM | -3.64% |
| Return on equity TTM | -37.98% |
| Profit margin | -55.89% |
| Book value | $2.29 |
| Market Capitalization | $756.2 million |
TTM: trailing 12 months
We're not expecting Maravai LifeSciences Holdings to pay a dividend over the next 12 months.
You may also wish to consider:
Over the last 12 months, Maravai LifeSciences Holdings's shares have ranged in value from as little as $1.665 up to $11.555. A popular way to gauge a stock's volatility is its "beta".
Beta is a measure of a share's volatility in relation to the market. The market (NASDAQ average) beta is 1, while Maravai LifeSciences Holdings's is 0.179. This would suggest that Maravai LifeSciences Holdings's shares are less volatile than average (for this exchange).
To put Maravai LifeSciences Holdings's beta into context you can compare it against those of similar companies.
Maravai LifeSciences Holdings, Inc. , a life sciences company, provides products that enable the development of drug therapies, vaccines, drug therapies, cell and gene therapies, and diagnostics North America, Europe, the Middle East, Africa, the Asia Pacific, and Latin and Central America. It operates in two segments, Nucleic Acid Production and Biologics Safety Testing. The Nucleic Acid Production segment manufactures and sells products for use in the fields of gene therapy, vaccines, nucleoside chemistry, and oligonucleotide therapy, as well as molecular diagnostics, including reagents used in the chemical synthesis, modification, labelling, and purification of deoxyribonucleic acid (DNA) and ribonucleic acid (RNA). This segment also offers messenger RNA, oligonucleotides, CleanCap capping technology-based oligonucleotide building blocks, and custom enzyme development and manufacturing; and research products for labeling and detecting proteins in cells and tissue samples. The Biologics Safety Testing segment sells analytical products for use in biologic manufacturing process development, including custom product-specific development antibody and assay development services. This segment also provides HCP ELISA kits, other bioprocess impurity and contaminant ELISA kits, ancillary reagents, viral clearance prediction kits, and custom services.
Some of the best paper trading apps to practice stock trading with fake money include Interactive Brokers, eToro, Charles Schwab and more.
These are the stocks to buy when you don’t have much to spend.
These are the best day trading apps, according to Finder’s comprehensive analysis.
Explore the best bonuses for opening a new brokerage account.
Some of the best stock trading apps for beginners include SoFi, Robinhood, Public, Stash, Opto and more. Compare your options here.
Want to buy and sell international stocks? Here are the top brokers to help you trade global markets.
These are the best discount brokers of 2025 according to Finder’s comprehensive review.
Compare the 7 best stock picking services, according to Finder’s analysis, and learn how to choose the best option for your needs.
Check out our picks of the best trading apps for beginners, options traders, hands-off investors and more.
See our picks of the best brokerage accounts, including Fidelity, SoFi, Charles Schwab, Public, Robinhood and E*TRADE .